Cepheid Reports 2009 Second Quart...(--- ----- --- --- ...),Health

Date:7/30/2009

--- ----- --- --- Net loss $(6,779) $(7,695) $(14,381) $(9,713) ======= ======= ======== ======= Basic and diluted net loss per share $(0.12) $(0.13) $(0.25) $(0.17) ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share 58,053 57,054 57,943 56,603 ====== ====== ====== ====== (1) See discussion in press release.

                                     CEPHEID

                 CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS
                                  (in thousands)


                                                         June 30, December 31,
                                                           2009       2008
                                                           ----       ----
                                                                       As
                                                                  Restated (1)
                                 ASSETS
    Current assets:
      Cash and cash equivalents                           $24,726    $23,478
      Restricted cash                                           -      1,500
      Short-term investments                               24,924          -
      Accounts receivable, net                             20,828     18,952
      Inventory                                            35,251     33,498
      Prepaid expenses and other current assets             2,485      4,636
                                                            -----      -----
    Total current assets                                  108,214     82,064
    Property and equipment, net                            22,780     24,10
'/>"/>
SOURCE  Cepheid
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results